Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
The neonatal Fc receptor (FcRn) preserves IgG by preventing lysosomal degradation, thereby extending IgG half-life. Inhibition of FcRn enhances the clearance of pathogenic IgG autoantibodies, resulting in rapid and reversible reductions in circulating AChR and MuSK antibodies without causing broad immunosuppression. This educational program for neurologists delivers a focused, clinically relevant update on FcRn blockade in the management of generalized myasthenia gravis (gMG), highlighting the pathophysiologic rationale for targeting FcRn and its translation into meaningful patient benefit.
Target Audience
This educational activity is directed toward neurologists, neurology nurses, specialty nurse practitioners and physician assistants, and other health care practitioners involved in managing generalized myasthenia gravis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the role of FcRN in the pathophysiology of generalized myasthenia gravis
- Evaluate emerging data for FcRN-targeted therapies for generalized myasthenia gravis in relation to treatment outcomes
- Integrate novel agents into individualized multidisciplinary management plans for patients with generalized myasthenia gravis
Abigail Schwaede, MD
Lurie Children's Hospital of Chicago
Chicago, IL
Disclosures: Abigal Schwaede, MD, has no relevant financial relationships with ineligible companies.
Alexis Lizarraga, MD, MS
Department of Neurology
University of Rochester Medical Center
Rochester, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Johnson & Johnson Pharmaceuticals, Med Learning Group; Grant/Research Funding: Alexion Pharmaceuticals, Argenx, Cabaletta Bio Inc.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here